Vanguard Group Inc. Acquires 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Vanguard Group Inc. lifted its position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 44.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,276,784 shares of the biotechnology company's stock after purchasing an additional 700,243 shares during the period. Vanguard Group Inc. owned about 5.01% of Capricor Therapeutics worth $31,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of CAPR. AlphaQuest LLC purchased a new stake in Capricor Therapeutics in the 4th quarter worth $78,000. New York State Common Retirement Fund boosted its stake in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 5,000 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Capricor Therapeutics in the fourth quarter worth about $91,000. Teacher Retirement System of Texas purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $141,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Capricor Therapeutics during the 3rd quarter valued at approximately $161,000. 21.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CAPR shares. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock traded up $1.61 during trading hours on Friday, reaching $11.25. The company's stock had a trading volume of 1,508,377 shares, compared to its average volume of 1,471,293. Capricor Therapeutics Inc has a one year low of $3.52 and a one year high of $23.40. The firm has a 50 day moving average price of $12.38 and a 200-day moving average price of $15.08. The stock has a market cap of $513.87 million, a P/E ratio of -10.61 and a beta of 4.65.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. As a group, sell-side analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.